$4.17
$0.00 (0.00%)
End-of-day quote: 05/15/2024
NasdaqCM:ALDX
Aldeyra Therapeutics Annual Report
| Year | Year | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rev. | Revenue |
|
$0.00M | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M | ||
| GM % | Gross Margin % |
|
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||
| OM | Operating Margin |
|
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||
| EPS | Earnings Per Share |
|
$0.00 | $-0.64 | $-1.06 | $-1.07 | $-1.11 | $-2.24 | $-1.79 | $-1.40 | $-1.65 | $-1.40 | $-2.51 |
| Div. | Dividends |
|
$0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||
| PR % | Payout Ratio % |
|
-0.00% | -0.00% | -0.00% | -0.00% | -0.00% | 0 | 0 | 0 | 0 | ||
| Sha. | Shares |
|
58.09m | 58.08m | 38.67m | 28.66m | 26.24m | 19.14m | 12.58m | 9.71m | 5.57m | ||
| OCF | Operating Cash Flow |
|
$-49356532.00M | $-42.56M | $-37.49M | $-44.98M | $-29.86M | $-19.22M | $-15.15M | $-9.31M | $-4.78M | ||
| FCF | Free Cash Flow |
|
$-50.70M | $-56.29M | $-37.49M | $-44.99M | $-30.12M | $-19.24M | $-18.83M | $-9.40M | $-4.79M | ||
| FCFS | Free Cash Flow Per Share |
|
$-0.97 | $-0.79 | $-1.10 | $-1.66 | $-1.39 | $-1.21 | $-1.34 | $-1.09 | $-1.25 |
